Peptidify
← Back to codex

Alpha-ketoglutarate (AKG/Ca-AKG)

Aliases: Alpha-Ketoglutarate · Ca-AKG

Last verified: 2026-09-23

Research chemicalLimited evidenceSmall moleculesLow interest

The short version

A Krebs-cycle metabolite — extends healthy lifespan in mice (Ca-AKG), popular in longevity stacks; also a sports supplement (AAKG). Key fact: Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical (healthspan extension); small human studies. Status: research chemical. Legal supplement.

Identity & type

Molecular type
mali molekul
Origin
A Krebs-cycle metabolite — extends healthy lifespan in mice (Ca-AKG), popular in longevity stacks; also a sports supplement (AAKG).

Mechanism of action

Dioxygenase cofactor (DNA/histone demethylases), anti-inflammatory, energy substrate.

not confirmed in humans

Dosing & routes

Official / clinical context

No approved official document exists for Alpha-ketoglutarate (AKG/Ca-AKG). Any protocols mentioned are to be read as information, not as a recommendation.

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

Ca-AKG 1–3 g/day; AAKG sports 3–6 g/day. Ca-AKG users report energy and recovery; sports AAKG — workout pump. Both effect groups are moderate.

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

Ca-AKG users report energy and recovery; sports AAKG — workout pump. Both effect groups are moderate.

Protocol — official vs community

Official / label

Supplement (Ca-AKG). The mouse lifespan study (2020) used drinking-water dosing; human equivalent unestablished.

  1. 011–2 g daily typical product dosing

Duration: Continuous.

Krebs-cycle intermediate with an intriguing mouse lifespan result and thin human data.

Community (anecdotal)

1 g AM / 1 g PM.

Cycle:
Continuous.
Break:
None.

Bryan Johnson's stack popularized it; the evidence hasn't caught up with the endorsement.

Human evidence

Human data are limited: small trials or case-series reports exist, without large randomized studies. Preclinical (healthspan extension); small human studies.

Preclinical evidence

Preclinical (healthspan extension); small human studies.

Known risks

  • Rare GI upset.characterized

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • Long-term human safety
  • Optimal dose and pharmacokinetics

Frequently asked questions

References

Systematic references are being expanded; verify sources directly before any decision.